Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 56
Filter
1.
J Low Genit Tract Dis ; 28(1): 84-90, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37924260

ABSTRACT

BACKGROUND: Lichen sclerosus (LS) is a chronic, inflammatory process affecting predominantly anogenital skin, with extragenital involvement in up to 20% of cases. The mainstay of therapy for anogenital LS is topical immunosuppression. However, in treatment-refractory cases, severe, or hypertrophic disease, systemic modalities may be used. Currently, there are no guidelines for systemic therapy in LS. OBJECTIVE: This study aimed to provide a review of the current literature on use of systemic therapies for LS, including demographic and clinical features of LS, as well as reported outcomes. METHODS: A primary literature search was conducted using the following databases: PubMed, Ovid, Scopus, and Web of Science, from the year the journal was published until June 2022. RESULTS: Ultimately, 71 studies consisting of 392 patients were included. Of these, 65% (n = 254) had anogenital disease, 9% (n = 36) had extragenital disease, and 19% (n = 73) had both anogenital and extragenital disease, and in 7% (n = 29) of cases, location was not specified. The most frequent therapies, stratified by total cases, included oral retinoids (n = 227), methotrexate (n = 59), hydroxychloroquine (n = 36), and systemic steroids (prednisone, methylprednisolone, prednisolone, oral triamcinolone, and other systemic steroids) (n = 60). Overall, 76% (n = 194) of anogenital, 94% (n = 34) of extragenital, and 81% (n = 59) of patients with both anogenital and extragenital involvement were reported to have clinical or symptomatic improvement. CONCLUSION: Overall, we found many therapies that have been used with reported success for extragenital and genital LS. However, future studies are needed to better define treatment outcomes and directly compare efficacy of different therapies for LS.


Subject(s)
Lichen Sclerosus et Atrophicus , Humans , Lichen Sclerosus et Atrophicus/drug therapy , Methotrexate , Treatment Outcome , Skin , Steroids/therapeutic use
2.
Am J Dermatopathol ; 45(8): 588-592, 2023 Aug 01.
Article in English | MEDLINE | ID: mdl-37462209

ABSTRACT

ABSTRACT: Several vulvar lichen sclerosus (VLS) clinical severity scales have recently been proposed. In this prospective case series, we characterized histopathology in the context of clinical severity in 6 treatment-naïve postmenopausal patients with VLS. The Vulvar Quality of Life Index (VQLI) and an adaptation of the 2018 International Society for the Study of Vulvovaginal Disease Delphi consensus VLS severity score were administered. Vulvar skin punch biopsies were obtained to measure inflammatory density, constituent inflammatory cells, thickness of the stratum corneum and other epidermal layers, dermal edema, and dermal sclerosis. Clinicopathologic correlations were assessed. Two cases demonstrated sparse inflammatory densities, 1 case demonstrated patchy and nodular inflammatory density, 1 case demonstrated dense lichenoid inflammatory density, and 2 cases demonstrated dense lichenoid and epitheliotropic inflammatory densities. Those patients who reported severe pruritus demonstrated the greatest lymphocytic inflammatory densities on histopathological examination. Both cases of ulceration or erosion were associated with severe VQLI scores. Severe VQLI scores were also associated with trends for higher average thickness of the epidermal layers and of dermal sclerosis. Altogether, histopathologic grading of biopsy sites may reflect clinical severity in patients with VLS.


Subject(s)
Lichen Sclerosus et Atrophicus , Vulvar Lichen Sclerosus , Female , Humans , Vulvar Lichen Sclerosus/pathology , Quality of Life , Sclerosis/pathology , Vulva/pathology , Epidermis/pathology , Lichen Sclerosus et Atrophicus/pathology
3.
J Am Acad Dermatol ; 85(2): 523-528, 2021 Aug.
Article in English | MEDLINE | ID: mdl-31437544

ABSTRACT

The prevalence of acute vulvovaginal involvement in toxic epidermal necrolysis can be as high as 70%; up to 28% of female patients will also develop chronic vulvovaginal sequelae. There is little consensus regarding prevention and treatment of the gynecologic sequelae of both Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). We review acute and chronic sequelae, including erosions, scar formation, chronic skin changes, urethral complications, adenosis, malignant transformation, vulvodynia, and dyspareunia. We provide comprehensive recommendations for acute and long-term vulvovaginal care in adult and pediatric SJS/TEN patients. Treatment should include an ultrapotent topical steroid, followed by a nonirritating barrier cream applied to vulvar and perineal lesions. A steroid should be used intravaginally along with vaginal dilation in all adults (but should be avoided in prepubertal adolescents) with vaginal involvement. Menstrual suppression should be considered in all reproductive age patients until vulvovaginal lesions have healed. Last, referrals for pelvic floor physical therapy and to surgical subspecialties should be offered on a case-by-case basis. This guide summarizes the current available literature combined with expert opinion of both dermatologists and gynecologists who treat a high volume of SJS/TEN patients.


Subject(s)
Stevens-Johnson Syndrome/complications , Vaginal Diseases/etiology , Vaginal Diseases/therapy , Vulvar Diseases/etiology , Vulvar Diseases/therapy , Female , Humans , Practice Guidelines as Topic , Stevens-Johnson Syndrome/diagnosis , Vaginal Diseases/prevention & control , Vulvar Diseases/prevention & control
4.
J Am Acad Dermatol ; 84(6): 1547-1553, 2021 Jun.
Article in English | MEDLINE | ID: mdl-32389716

ABSTRACT

BACKGROUND: Patient outcomes are improved when dermatologists provide inpatient consultations. Inpatient access to dermatologists is limited, illustrating an opportunity to use teledermatology. Little is known about the ability of dermatologists to accurately diagnose disease and manage inpatients with teledermatology, particularly when using nondermatologist-generated clinical data. METHODS: This prospective study assessed the ability of teledermatology to diagnose disease and manage 41 dermatology consultations from a large urban tertiary care center, using internal medicine referral documentation and photographs. Twenty-seven dermatology hospitalists were surveyed. Interrater agreement was assessed by the κ statistic. RESULTS: There was substantial agreement between in-person and teledermatology assessment of the diagnosis with differential diagnosis (median κ = 0.83), substantial agreement in laboratory evaluation decisions (median κ = 0.67), almost perfect agreement in imaging decisions (median κ = 1.0), and moderate agreement in biopsy decisions (median κ = 0.43). There was almost perfect agreement in treatment (median κ = 1.0), but no agreement in follow-up planning (median κ = 0.0). There was no association between raw photograph quality and the primary plus differential diagnosis or primary diagnosis alone. LIMITATIONS: Selection bias and single-center nature. CONCLUSIONS: Teledermatology may be effective in the inpatient setting, with concordant diagnosis, evaluation, and management decisions.


Subject(s)
Dermatology/methods , Hospitalization , Remote Consultation/methods , Skin Diseases/diagnosis , Adult , Aged , Feasibility Studies , Female , Hospitalists/statistics & numerical data , Humans , Male , Middle Aged , Observer Variation , Photography , Prospective Studies , Skin/diagnostic imaging , Surveys and Questionnaires/statistics & numerical data , Tertiary Care Centers
5.
J Am Acad Dermatol ; 82(6): 1287-1298, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31712170

ABSTRACT

The most problematic vulvovaginal conditions are familiar to dermatologists but may exhibit distinct clinical features or medication management because of the anatomic location. The second article in this continuing medical education series focuses on management pearls for treating vulvar diseases. We highlight key conditions, such as lichen sclerosus, erosive lichen planus, and vulvodynia. In addition, we review conditions that dermatologists may be less familiar with, such as plasma cell vulvitis, desquamative inflammatory vaginitis, vulvar aphthae, and low estrogen states. Nearly 1 in 6 women experience undiagnosed and untreated vulvovaginal discomfort at some point in their lives. Physicians who treat vulvar disorders will improve the quality of life of countless women.


Subject(s)
Skin Diseases/diagnosis , Skin Diseases/therapy , Vagina/pathology , Vulvar Diseases/diagnosis , Vulvar Diseases/therapy , Adult , Atrophy/diagnosis , Atrophy/therapy , Child , Crohn Disease/complications , Female , Humans , Lichen Planus/diagnosis , Lichen Planus/therapy , Plasma Cells/pathology , Skin Diseases/etiology , Skin Ulcer/diagnosis , Skin Ulcer/drug therapy , Vaginitis/diagnosis , Vaginitis/drug therapy , Vulvar Diseases/etiology , Vulvar Lichen Sclerosus/drug therapy , Vulvitis/diagnosis , Vulvitis/drug therapy , Vulvodynia/diagnosis
6.
J Am Acad Dermatol ; 82(6): 1277-1284, 2020 Jun.
Article in English | MEDLINE | ID: mdl-31712174

ABSTRACT

Patients with vulvar dermatoses often delay seeking medical treatment because of anxiety and embarrassment. Moreover, women frequently self-treat with various home remedies and see multiple clinicians before presenting to a dermatologist. Despite serving as the primary providers for patients with vulvovaginal symptoms, gynecologists typically receive limited training in the causes and management of these conditions. Dermatologists are experts in the evaluation and management of cutaneous disease and should be the caretakers of all skin, including the genitalia. Vulvar disorders are underrecognized by dermatologists for numerous reasons: inadequate training, lack of comfort with both interview and examination techniques, and unfamiliarity with normal anatomic variations. The first article in this continuing medical education series on vulvar dermatoses reviews the fundamentals, approach, and techniques that can be used to ensure a successful visit for both patient and provider.


Subject(s)
Patient Education as Topic , Physical Examination , Skin Diseases/diagnosis , Vulvar Diseases/diagnosis , Adult , Anatomic Variation , Child , Documentation , Female , Humans , Medical History Taking , Skin Diseases/etiology , Vulva/anatomy & histology , Vulvar Diseases/etiology
7.
J Am Acad Dermatol ; 82(6): 1553-1567, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32151629

ABSTRACT

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions with high morbidity and mortality. Supportive care management of SJS/TEN is highly variable. A systematic review of the literature was performed by dermatologists, ophthalmologists, intensivists, and gynecologists with expertise in SJS/TEN to generate statements for supportive care guideline development. Members of the Society of Dermatology Hospitalists with expertise in SJS/TEN were invited to participate in a modified, online Delphi-consensus. Participants were administered 9-point Likert scale questionnaires regarding 135 statements. The RAND/UCLA Appropriateness Method was used to evaluate and select proposed statements for guideline inclusion; statements with median ratings of 6.5 to 9 and a disagreement index of ≤1 were included in the guideline. For the final round, the guidelines were appraised by all of the participants. Included are an evidence-based discussion and recommendations for hospital setting and care team, wound care, ocular care, oral care, urogenital care, pain management, infection surveillance, fluid and electrolyte management, nutrition and stress ulcer prophylaxis, airway management, and anticoagulation in adult patients with SJS/TEN.


Subject(s)
Stevens-Johnson Syndrome/therapy , Adult , Humans
19.
J Cutan Pathol ; 44(3): 296-299, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28035700

ABSTRACT

We present the case of a 28-year-old male with a history of human immunodeficiency virus (HIV) with a 1-month history of a steadily enlarging, firm painful lesion on the right posterior shoulder. The patient was initially treated for cellulitis given his clinical picture. Histopathologic examination revealed an angiocentric and dermal proliferation of markedly atypical lymphoid cells with numerous mitoses and apoptotic bodies along with broad zones of necrosis. Biopsy revealed the presentation to be consistent with NK/T-cell lymphoma. The cutaneous lesions from NK/T-cell lymphoma can often be initially mistaken for cellulitis, therefore this malignancy should be included on the differential in a patient HIV/acquired immune deficiency syndrome (AIDS).


Subject(s)
HIV Infections/complications , Lymphoma, Extranodal NK-T-Cell/diagnosis , Biomarkers, Tumor/analysis , Cellulitis/pathology , Diagnosis, Differential , Humans , Immunohistochemistry , Lymphopenia , Male , Skin Neoplasms/pathology
20.
J Cutan Pathol ; 44(1): 15-19, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27686553

ABSTRACT

BACKGROUND: Angiosarcoma is a malignancy of vascular endothelial cells which may arise secondarily as a complication of lymphedema, including chronic lymphedema of morbid obesity. Amplifications in MYC are frequently present in secondary angiosarcoma (arising in irradiated sites and chronic lymphedema) and less frequently in primary cutaneous angiosarcoma. OBJECTIVE: To describe the presence of MYC amplifications in two cases of cutaneous angiosarcoma secondary to chronic lymphedema of morbid obesity. METHODS: This study is a case series of two patients with cutaneous angiosarcoma. Clinical data was retrieved from the medical records. Histopathological analysis of the biopsy specimens was performed, including immunohistochemistry, along with fluorescence in situ hybridization. RESULTS: Angiosarcoma arose in the setting of massive chronic lymphedema complicating morbid obesity without other predisposing risk factors. Both cases exhibited epithelioid cell morphology and high-level MYC amplification. CONCLUSION: We report MYC amplification in two cases of angiosarcoma arising in massive chronic lymphedema of morbid obesity.


Subject(s)
Hemangiosarcoma/genetics , Proto-Oncogene Proteins c-myc/genetics , Skin Neoplasms/genetics , Chronic Disease , Female , Gene Amplification , Hemangiosarcoma/complications , Humans , In Situ Hybridization, Fluorescence , Lymphedema/etiology , Middle Aged , Obesity, Morbid/complications , Skin Neoplasms/complications
SELECTION OF CITATIONS
SEARCH DETAIL